Prime Medicine is a Cambridge, Massachusetts biotechnology company developing gene editing medicines for genetic diseases. It last closed at $3.84 on Nov 17, down 8.35% on the day. In the past 30 days there were 2 dark pool prints totaling $283K, the largest $165K.
Only 1 firm rated PRME in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 82.3% upside
Based on 1 analyst who set a price target on PRME in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $3.84.
Low $7.00Avg $7.00High $7.00
Blue marker: last close $3.84
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
Chardan CapitalMaintained
Sep 25Buy$7
Chardan CapitalMaintained
Aug 25Buy$7
BMO CapitalInitiated
Aug 19Buy$9
HC Wainwright & Co.Reiterated
Aug 10Buy$8
HC Wainwright & Co.Upgrade
Jun 29Buy$8
Date
Firm
Action
Rating
Price target
Sep 25
Chardan Capital
Maintained
Buy
$7
Aug 25
Chardan Capital
Maintained
Buy
$7
Aug 19
BMO Capital
Initiated
Buy
$9
Aug 10
HC Wainwright & Co.
Reiterated
Buy
$8
Jun 29
HC Wainwright & Co.
Upgrade
Buy
$8
Loading…
Technical Analysis
PRME · as of the Nov 17 close · updated after every close
Moving sideways
The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the swing low (Nov 12) at $3.73, and the nearest resistance the swing high (Sep 4) at $3.86.
Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 12.3%/day
Key levels
$5.9152 week high+53.9%
$4.3120 day average+12.2%
$4.23Pivot R1+10.2%
$4.02Pivot+4.7%
$3.86Swing high (Sep 4)+0.5%
$3.84Last close
$3.73Swing low (Nov 12)−2.9%
$3.7150 day average−3.4%
$3.64Pivot S1−5.2%
$3.55100 day average−7.6%
$3.51200 day average−8.6%
$2.6752 week low−30.5%
Indicators
RSI (14)
46.82
Middle of its range
Neutral
MACD
0.09
Below its signal line
Bearish
Stochastic
18.7
Near the bottom of its range
Oversold
ADX (14)
24.0
Weak trend
Williams %R
-95.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-49.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−15.6%
Change over 10 sessions
Bearish
ATR (14)
$0.47
Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 20.0%/day
Key levels
$5.9152 week high+53.9%
$4.3120 day average+12.2%
$4.23Pivot R1+10.2%
$4.02Pivot+4.7%
$3.86Swing high (Sep 4)+0.5%
$3.84Last close
$3.73Swing low (Nov 12)−2.9%
$3.7150 day average−3.4%
$3.64Pivot S1−5.2%
$3.55100 day average−7.6%
$3.51200 day average−8.6%
$2.6752 week low−30.5%
Indicators
RSI (14)
52.29
Middle of its range
Neutral
MACD
0.20
Above its signal line
Bullish
Stochastic
47.5
Middle of its range
Neutral
ADX (14)
24.2
Weak trend
Williams %R
-65.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
72.1
Oversold below −100, overbought above 100
Neutral
Rate of change
+22.7%
Change over 10 sessions
Bullish
ATR (14)
$0.77
Typical daily range, 20.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for PRME
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PRME did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PRME usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PRME has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRME is in one of them and how their past PRME trades turned out.
Prime Medicine is a biotechnology company based in Cambridge, Massachusetts. It develops gene editing medicines built on a technology called Prime Editing, which is designed to rewrite specific sections of DNA without cutting both strands of the double helix. The company's programs target inherited diseases, with early focus on conditions affecting the liver and lungs and on certain blood disorders. Its medicines are intended for patients with these genetic conditions and the doctors who treat them.